Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of efgartigimod in generalized myasthenia gravis
NL-OMON47956Phase 3Completed
- Sponsor
- argenx
- Start
- Jul 2019
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Efgartigimod with Placebo (2 arms). Primary endpoint: MG-ADL responders in AChR-antibody seropositive population. Started Jul 2019; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON47956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47956.